Payel Das

• Led end-to-end facility readiness and GMP compliance, including IQ/OQ/PQ, SOP authoring, and consumable lifecycle management, enabling seamless scale-up operations at a new CAR‑T site in Bangalore, Attibele
• Drove successful tech transfer from Process Development to Manufacturing, delivering 8 at-scale BCMA CAR‑T batches with improved process robustness and reproducibility along with Consistancy Runs for Regulatory submission.
• Spearheaded process optimization initiatives to enhance manufacturing efficiency and consistency
• Owned critical process development studies, optimizing cytokine strategies and establishing apheresis/PBMC stability windows, strengthening product quality and defining key process parameters.

• Led monoclonal antibody discovery using single B-cell and hybridoma platforms across multiple species.
• Executed client-driven antibody engineering projects including mouse and chimeric antibodies.
• Performed recombinant antibody generation and V-gene cloning workflows.

• Isolated and characterized monoclonal antibodies from HIV infected patient which are mainly Indian clade C specific broadly neutralizing monoclonal antibodies (bNabs)
• Focused on developing broadly neutralizing antibodies against SARS-COV2
• Studying highly efficient and unique 'B'-cell based antibody identification process from immunized animals.
• Handling client projects to develop hybridoma and mouse/chimeric recombinant antibodies.
• Working on Hybrid cells as well as single B cells for production of unique V-gene antibodies from rabbit, mouse, human cells.

• Completion of project named 'Characterization of , as a potential therapeutic target against in lung carcinoma.'